Table 2.
HR from fitting an unweighted Cox regression model with time fixed covariates at entry
| Panel A) | Unadjusted and adjusted hazard ratio of treatment failure endpoint& | |||
|---|---|---|---|---|
| Unadjusted HR (95% CI) | p-value | Adjusted* HR (95% CI) | p-value | |
| GSS (>20% window) | ||||
| 3 | 1 | 1 | ||
| 0–2.75 | 2.29 (1.24, 4.21) | 0.008 | 2.18 (1.16, 4.09) | 0.015 |
| GSS (>5% window) | ||||
| 3 | 1 | 1 | ||
| 0–2.75 | 1.91 (1.10, 3.34) | 0.022 | 1.74 (0.99, 3.07) | 0.056 |
| GSS (5–20% window £ ) | ||||
| 3 | 1 | 1 | ||
| 0–2.75 | 1.72 (0.95, 3.10) | 0.074 | 1.56 (0.85, 2.84) | 0.150 |
| GSS (>2% window) | ||||
| 3 | 1 | 1 | ||
| 0–2.75 | 1.69 (1.04, 2.75) | 0.033 | 1.66 (1.01, 2.74) | 0.046 |
| GSS (2–20% window £ ) | ||||
| 3 | 1 | 1 | ||
| 0–2.75 | 1.57 (0.95, 2.60) | 0.079 | 1.54 (0.93, 2.56) | 0.096 |
| Panel B) | Subsets of participants who started a NNRTI-based regimen | |||
| GSS (>20% window) | ||||
| 3 | 1 | 1 | ||
| 0–2.75 | 3.12 (1.61, 6.05) | <.001 | 2.93 (1.47, 5.84) | 0.002 |
| GSS (>5% window) | ||||
| 3 | 1 | 1 | ||
| 0–2.75 | 2.58 (1.38, 4.81) | 0.003 | 2.25 (1.19, 4.25) | 0.012 |
| GSS (5–20% window £ ) | ||||
| 3 | 1 | 1 | ||
| 0–2.75 | 2.27 (1.17, 4.42) | 0.016 | 1.99 (1.01, 3.90) | 0.046 |
| GSS (>2% window) | ||||
| 3 | 1 | 1 | ||
| 0–2.75 | 2.35 (1.35, 4.12) | 0.003 | 2.32 (1.32, 4.09) | 0.003 |
| GSS (2–20% window £ ) | ||||
| 3 | 1 | 1 | ||
| 0–2.75 | 2.16 (1.21, 3.85) | 0.009 | 2.15 (1.20, 3.86) | 0.011 |
*
adjusted for geographical region, baseline HIV-RNA, intervention arm of START (immediate vs. differed) and year of starting ART
&
Pure confirmed VF or a single VL>200 copies/mL followed by a ART change
£
Restricting to those with GSS
$
≥2; this was done to exclude those who could be detected as participants initiating a suboptimal regimen by Sanger sequence alone
$
HIVDB v8.6 with >20% threshold